Publication | Closed Access

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

Treatment And PreventionMedicineAntiviral Drug DevelopmentAntiviral TherapyVirologyWeek 124PharmacotherapyAntiviral DrugHivPharmacologyFlair StudyLong-acting CabotegravirDrug Resistance